Your browser doesn't support javascript.
loading
Transperineal intraprostatic injection of botulinum neurotoxin A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study.
El-Dakhakhny, Amr S; Gharib, Tarek; Issam, Ahmed; El-Karamany, Tarek M.
Afiliação
  • El-Dakhakhny AS; Department of Urology, Faculty of Medicine, Benha University, Benha, Egypt.
  • Gharib T; Department of Urology, Faculty of Medicine, Benha University, Benha, Egypt.
  • Issam A; Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt.
  • El-Karamany TM; Department of Urology, Faculty of Medicine, Benha University, Benha, Egypt.
Arab J Urol ; 17(4): 270-278, 2019.
Article em En | MEDLINE | ID: mdl-31723444
Objectives: To evaluate transperineal intraprostatic injection of botulinum neurotoxin A (BoNT-A) in patients with lower urinary tract symptoms (LUTS) secondary to benign prostate hyperplasia (BPH) who failed to respond to 6-month medical treatment compared with transurethral resection of the prostate (TURP). Patients and methods: In all, 92 men were divided into TURP and BoNT-A groups after being evaluated using the International Prostate Symptom Score (IPSS) and five-item version of the International Index of Erectile Function, estimation of serum total prostate-specific antigen (tPSA), ultrasonographic estimation of prostatic volume (PV), and uroflowmetry determination of voiding volume (VV), maximum urinary flow rate (Qmax) and post-void residual urine volume (PVR). BoNT-A (200 U diluted in 3 mL saline) was injected, using a 22-G spinal needle under transrectal ultrasonography guidance, with 1-mL in each lobe. Patients were assessed 3-monthly for 12 months. Results: The IPSS significantly decreased in all patients with a non-significant difference between the groups. The mean VV and Qmax increased, whilst PVR, PV and serum tPSA significantly decreased. Patients who showed deterioration at 12 months were re-evaluated and underwent TURP. BoNT-A injection significantly maintained erectile function compared with TURP. Conclusion: Intraprostatic BoNT-A injection reduced PV with subsequent increases in VV and Qmax, and decreases in PVR and serum tPSA level. Intraprostatic BoNT-A injection allowed surgery sparing in >70% and preserved erectile function in 91.3% of patients. Abbreviations: BoNT-A: botulinum neurotoxin A; HRQOL: health-related quality of life; IIEF-5: five-item version of the International Index of Erectile Function; PV: prostatic volume; PVR: post-void residual urine volume; Qmax: maximum urinary flow rate; tPSA: total PSA; VV: voided volume.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline Idioma: En Revista: Arab J Urol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Egito

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Diagnostic_studies / Guideline Idioma: En Revista: Arab J Urol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Egito